Emperor Capital (00717) announced its interim financial results with a net profit of HK$38.955 million, a year-on-year decrease of 30.59%.
Emperor Capital Group (00717) announced its interim results for the six months ended 31 March 2026, with a total revenue of approximately HK$148 million, a decrease of 63.31% compared to the same period last year. Net profit was HK$38.955 million, a decrease of 30.59% year-on-year, with basic earnings per share of 0.58 HK cents.
Emperor Capital (00717) announced its interim performance for the six months ending March 31, 2026, with total income of approximately HK$148 million, a decrease of 63.31% year-on-year; net profit of HK$38.955 million, a decrease of 30.59% year-on-year; and basic earnings per share of 0.58 HK cents.
Related Articles
The equity of GUANZE MEDICAL(02427) is highly concentrated.
OIWAHPAWN (01319) announced annual performance with a net profit attributable to shareholders of HK$82.609 million, representing a year-on-year increase of 47.8%.
BIOSTAR PHARM-B (02563): Four clinical research achievements of Utidelon were selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The equity of GUANZE MEDICAL(02427) is highly concentrated.
OIWAHPAWN (01319) announced annual performance with a net profit attributable to shareholders of HK$82.609 million, representing a year-on-year increase of 47.8%.
BIOSTAR PHARM-B (02563): Four clinical research achievements of Utidelon were selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
